Last reviewed · How we verify
Photopheresis
Photopheresis is a Small molecule drug developed by Eastern Cooperative Oncology Group. It is currently in Phase 2 development. Also known as: 8-methoxypsoralen, Uvadex ®, Methoxsalen.
Photopheresis is a medical treatment that involves separating blood into its components, treating the buffy coat with a chemical called 8-methoxypsoralen, and then exposing it to ultraviolet light. This process causes the treated cells to undergo apoptosis, or programmed cell death, due to DNA crosslinking by the activated 8-methoxypsoralen.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Photopheresis |
|---|---|
| Also known as | 8-methoxypsoralen, Uvadex ®, Methoxsalen |
| Sponsor | Eastern Cooperative Oncology Group |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD (PHASE2)
- ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants (PHASE1)
- Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (PHASE2)
- Extracorporeal Photopheresis in Sezary Syndrome
- Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus (EARLY_PHASE1)
- EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Photopheresis CI brief — competitive landscape report
- Photopheresis updates RSS · CI watch RSS
- Eastern Cooperative Oncology Group portfolio CI
Frequently asked questions about Photopheresis
What is Photopheresis?
Who makes Photopheresis?
Is Photopheresis also known as anything else?
What development phase is Photopheresis in?
Related
- Manufacturer: Eastern Cooperative Oncology Group — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: 8-methoxypsoralen, Uvadex ®, Methoxsalen
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing